-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Odyssey Health, Inc. Provides Update on Company and the Progress of Concussion Drug Development
Odyssey Health, Inc. Provides Update on Company and the Progress of Concussion Drug Development
Las Vegas, Nevada, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, today presents a Company update and recap of its concussion drug development program. Concussions represent an 'unmet' medical need and affect tens of millions worldwide.
Odyssey acquired the intellectual property and all rights to the concussion drug in March 2021. Since the acquisition, Odyssey has added key industry experts to its management, made significant progress in the drug development program, and completed a Phase I human clinical trial. Key successes include:
- Adding two key executives to the management team that have pertinent pharmaceutical experience bringing drugs through the clinical process and to the market.
- Completion of FDA-required IND enabling studies for a Phase I human trial. This work was performed in partnership with multiple GMP/GLP third party vendors.
- Development of a nanoparticle spray-dried formulation for intranasal delivery to enhance brain uptake. This work was performed in partnership with our UK partner under GMP regulations.
- Development and GMP manufacture of our novel breath-propelled intranasal delivery device with our California based engineering partner.
- Patent application filed for our novel breath-propelled intranasal delivery device.
- Contracted with world-class contract research organizations, Avance Clinical Pty, Ltd. and Nucleus Networks to conduct the Phase I clinical trial.
- Excellent compliance of our breath-propelled intranasal delivery device in the Phase I trial.
- Completion of the Phase I human clinical trial, proving the drug is safe and well tolerated.
- Phase I human clinical trial showed no drug accumulation through the 10-day patient follow-up visit.
- Ongoing drug stability at elevated temperatures showing no degradation
- Raised over $5 million to support the company and its development efforts and access to an equity line with Lincoln Park Capital for up to $10 million.
About Odyssey Health Inc. (formerly Odyssey Group International, Inc.)
Odyssey Health Inc. (OTC: ODYY) is a medical company with a focus in the area of life-saving medical solutions. Odyssey's corporate mission is to create, acquire and develop distinct assets, intellectual property, and exceptional technologies that provide meaningful medical solutions. The company is focused on areas that have an identified technological advantage, provide superior clinical utility, and have a substantial market opportunity. For more information, visit the company's website at
We encourage our shareholders to visit our corporate social media accounts for updates:
About Our Drug Candidate
Our drug candidate is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of moderate traumatic brain injury. In preclinical studies, the drug has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids. Animal models of concussion demonstrated that the drug reduces the behavioral pathology associated with brain injury symptoms such as memory impairment, anxiety, and motor/sensory performance. Additionally, the drug is lipophilic and in pre-clinical studies has shown it can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation in the brain while restoring proper blood flow. Our novel breath-propelled, intranasal brain-drug delivery device is designed with a novel drug dispensing system that creates an effective airflow for depositing concentrated drug deep into the nasal cavity and onto the olfactory region, this could allow for quick and direct diffusion into the brain.
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to continue to raise needed funds, successfully complete additional clinical studies, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.
Inquiries:
Odyssey Health
info@odysseyhealthinc.com
Las Vegas, Nevada, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, today presents a Company update and recap of its concussion drug development program. Concussions represent an 'unmet' medical need and affect tens of millions worldwide.
2022年11月23日,内华达州拉斯维加斯(Global Newswire)--奥德赛健康公司(OTC:ODYY),F/K/a奥德赛集团国际有限公司,一家专注于开发独特的、增强生命的医疗产品的公司,今天向公司介绍了其脑震荡药物开发计划的最新情况。脑震荡代表着一种未得到满足的医疗需求,影响着全球数千万人。
Odyssey acquired the intellectual property and all rights to the concussion drug in March 2021. Since the acquisition, Odyssey has added key industry experts to its management, made significant progress in the drug development program, and completed a Phase I human clinical trial. Key successes include:
奥德赛于2021年3月获得了脑震荡药物的知识产权和所有权利。自收购以来,奥德赛公司的管理层增加了关键的行业专家,在药物开发计划方面取得了重大进展,并完成了一期人体临床试验。主要成功案例包括:
- Adding two key executives to the management team that have pertinent pharmaceutical experience bringing drugs through the clinical process and to the market.
- Completion of FDA-required IND enabling studies for a Phase I human trial. This work was performed in partnership with multiple GMP/GLP third party vendors.
- Development of a nanoparticle spray-dried formulation for intranasal delivery to enhance brain uptake. This work was performed in partnership with our UK partner under GMP regulations.
- Development and GMP manufacture of our novel breath-propelled intranasal delivery device with our California based engineering partner.
- Patent application filed for our novel breath-propelled intranasal delivery device.
- Contracted with world-class contract research organizations, Avance Clinical Pty, Ltd. and Nucleus Networks to conduct the Phase I clinical trial.
- Excellent compliance of our breath-propelled intranasal delivery device in the Phase I trial.
- Completion of the Phase I human clinical trial, proving the drug is safe and well tolerated.
- Phase I human clinical trial showed no drug accumulation through the 10-day patient follow-up visit.
- Ongoing drug stability at elevated temperatures showing no degradation
- Raised over $5 million to support the company and its development efforts and access to an equity line with Lincoln Park Capital for up to $10 million.
- 在管理团队中增加两名关键高管,他们拥有相关的制药经验,将药物带入临床过程并推向市场。
- 完成FDA要求的第一阶段人体试验的IND使能研究。这项工作是与多家GMP/GLP第三方供应商合作进行的。
- 用于鼻腔给药以增强脑摄取的纳米颗粒喷雾干燥制剂的开发。这项工作是根据GMP法规与我们的英国合作伙伴合作完成的。
- 与总部位于加州的工程合作伙伴共同开发和GMP制造我们的新型呼吸推进鼻腔给药装置。
- 我们的新型呼吸推进鼻腔给药装置申请了专利。
- 与世界级合同研究机构、Avance临床药业有限公司和Nucleus Networks签订合同,进行一期临床试验。
- 我们的呼吸推进鼻腔给药装置在第一阶段试验中表现出极好的依从性。
- 完成了第一阶段的人体临床试验,证明该药物是安全的,耐受性良好。
- I期人体临床试验显示,经过10天的患者随访,没有药物积聚。
- 持续的药物在高温下的稳定性显示没有降解
- 筹集了500多万美元,以支持公司及其发展努力,并以高达1000万美元的价格获得与林肯公园资本的股权额度。
About Odyssey Health Inc. (formerly Odyssey Group International, Inc.)
Odyssey Health Inc. (OTC: ODYY) is a medical company with a focus in the area of life-saving medical solutions. Odyssey's corporate mission is to create, acquire and develop distinct assets, intellectual property, and exceptional technologies that provide meaningful medical solutions. The company is focused on areas that have an identified technological advantage, provide superior clinical utility, and have a substantial market opportunity. For more information, visit the company's website at
关于奥德赛健康公司(前身为奥德赛国际集团)
奥德赛健康公司(场外交易代码:ODYY)是一家专注于拯救生命的医疗解决方案领域的医疗公司。奥德赛的公司使命是创造、收购和开发独特的资产、知识产权和特殊技术,提供有意义的医疗解决方案。该公司专注于具有公认的技术优势、提供卓越的临床实用价值和具有重大市场机会的领域。欲了解更多信息,请访问该公司网站:
We encourage our shareholders to visit our corporate social media accounts for updates:
我们鼓励我们的股东访问我们的企业社交媒体帐户以获取最新消息:
About Our Drug Candidate
Our drug candidate is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of moderate traumatic brain injury. In preclinical studies, the drug has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids. Animal models of concussion demonstrated that the drug reduces the behavioral pathology associated with brain injury symptoms such as memory impairment, anxiety, and motor/sensory performance. Additionally, the drug is lipophilic and in pre-clinical studies has shown it can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation in the brain while restoring proper blood flow. Our novel breath-propelled, intranasal brain-drug delivery device is designed with a novel drug dispensing system that creates an effective airflow for depositing concentrated drug deep into the nasal cavity and onto the olfactory region, this could allow for quick and direct diffusion into the brain.
关于我们的毒品候选人
我们的候选药物是一种正在开发的用于治疗中度创伤性脑损伤的完全合成的非自然发生的神经类固醇。在临床前研究中,该药物已显示出与相关神经类固醇相同的神经保护作用,如果不是更好的话。脑震荡的动物模型表明,该药物减少了与脑损伤症状相关的行为病理,如记忆障碍、焦虑和运动/感觉表现。此外,这种药物是亲脂性的,临床前研究表明,它可以很容易地穿过血脑屏障,迅速消除大脑中的肿胀、氧化应激和炎症,同时恢复适当的血液流动。我们的新型呼吸推进、鼻腔脑内给药装置设计了一种新的药物分配系统,该系统创建了有效的气流,将浓缩药物深入鼻腔并沉积到嗅觉区域,这可以允许快速和直接地扩散到大脑中。
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to continue to raise needed funds, successfully complete additional clinical studies, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.
前瞻性陈述
本新闻稿可能包含1995年私人证券诉讼改革法中“安全港”条款所指的前瞻性陈述。此类陈述是基于我们目前的预期,仅代表截至本文发布之日的情况。由于各种因素和不确定因素,我们的实际结果可能与任何前瞻性陈述中表达的结果大不相同和相反,这些因素和不确定因素包括我们继续筹集所需资金的能力,成功完成其他临床研究的能力,我们成功开发产品的能力,我们市场的快速变化,对我们未来产品的需求变化,以及立法、法规、竞争发展和总体经济状况。
Inquiries:
Odyssey Health
info@odysseyhealthinc.com
查询:
奥德赛健康
电子邮箱:Info@odyseyHealth Thinc.com
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧